Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Freshworks Inc (FRSH) vs Zoetis Inc (ZTS) Price & Performance

Freshworks IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Freshworks Inc vs Zoetis Inc — how do they compare? Freshworks Inc trades at $13.85 (market cap $3.56B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 8.5× Freshworks Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Zoetis Inc for 70 Days on average.

FRSHZTS
Market Cap
$3.56B$30.20B
Volume
9,066,4546,175,327
Sector
TechnologyHealth
52-Week High
$13.92$147.53
52-Week Low
$6.88$69.09
Typical Hold Time
39 Days70 Days
Enterprise Value
$2.93B$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Freshworks Inc

Freshworks (FRSH) trades at $13.86, up 1.91% today, reflecting positive momentum following its Q2 2026 earnings beat. The stock exhibits a bullish technical trend with strong moving average signals, though the RSI suggests it may be approaching overbought territory. Fundamentally, the company has achieved a significant turnaround, posting its first GAAP profitable quarter in 2026 with revenue growth of 16% year-over-year, driven by strength in its employee experience portfolio and cost discipline.

The outlook is positive, supported by a 50% analyst buy rating and a consensus price target of $14.60, implying modest upside. Key opportunities include continued AI monetization and market share gains, while risks involve heightened competition in the SaaS sector and the need to sustain recent profitability improvements amid economic uncertainty.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FRSH
0% Buy100% Sell
Avg holding period · 39 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Freshworks Inc

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.

Read more on FRSH →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →